ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 167

Association Of Functional Polymorphisms In IRF2 With Systemic Lupus Erythematosus In a Japanese Population

Aya Kawasaki1, Hiroshi Furukawa2, Nao Nishida3, Eiji Warabi4, Yuya Kondo5, Satoshi Ito6, Isao Matsumoto7, Makio Kusaoi8, Akiko Suda9, Shouhei Nagaoka10, Keigo Setoguchi11, Tatsuo Nagai12, Shunsei Hirohata13, Katsushi Tokunaga14, Yoshinari Takasaki15, Hiroshi Hashimoto16, Takayuki Sumida5, Shigeto Tohma2 and Naoyuki Tsuchiya1, 1Molecular and Genetic Epidemiology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 2Clinical Research Center for Allergy and Rheumatology, Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan, 3Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Ichikawa, Japan, 4Environmental Molecular Biology Laboratory, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 5Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, 6Niigata Rheumatic Center, Shibata, Japan, 7Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, 8Department of Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan, 9Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 10Department of Rheumatology, Yokohama Minami Kyousai Hospital, Yokohama, Japan, 11Allergy and Immunological Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan, 12Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan, 13Int Med/Rheumatol & Infec Dis, Kitasato University School of Medicine, Sagamihara, Japan, 14Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 15Department of Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 16Juntendo University School of Medicine, Tokyo, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Disease susceptibility, interferons, polymorphism and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Genetics and Genomics of Rheumatic Disease I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Interferon regulatory factor (IRF) families are transcription factors involved in type I interferon (IFN) pathway. Recent genetic studies identified association of IRF family genes, IRF5, IRF7, and IRF8, with systemic lupus erythematosus (SLE). IRF2 is thought to negatively regulate the type I IFN signals. In addition, IRF2 has a role in induction of Th1 differentiation and NK cell development. So far, association of IRF2 with SLE has not been published. In this study, we conducted an association study to examine whether IRF2 contributes to susceptibility to SLE in a Japanese population.

Methods:

A case-control association study was performed in 501 Japanese patients with SLE and 551 healthy controls on 46 tag SNPs in the IRF2 gene, selected based on linkage disequilibrium (LD) and minor allele frequencies (r2≥0.8, minor allele frequency≥0.05), using the DigiTag2 and the TaqMan allele discrimination assays. To identify functional SNPs, resequencing of the IRF2 region was performed using the next-generation sequencing. Effect of IRF2 SNPs on transcriptional activity was analyzed using a luciferase assay.

Results:

Among the IRF2 tag SNPs, rs13146124T in intron 1 was most significantly associated with SLE (dominant model, P=7.4X10-4, odds ratio [OR] 1.60, 95% confidence interval [CI] 1.22-2.11). Resequencing identified SNPs in LD with rs13146124. Eight SNPs including rs62339994 were in almost absolute LD with rs13146124 (r2: 0.98-1), whereas rs66801661 showed moderate LD (r2: 0.52).

We next examined association of rs66801661 with SLE. rs66801661A allele was significantly increased in SLE (allelic model, P=3.7X10-4, OR 1.75, 95%CI 1.29-2.39). Haplotype analysis identified three haplotypes constituted by rs66801661 and rs13146124, and the haplotype carrying both of the risk alleles, rs66801661A – rs13146124T, was significantly increased in SLE (SLE: 10.8%, control: 6.4%, permutation P=2.0X10-4). On the other hand, the haplotype formed by the non-risk alleles, rs66801661G – rs13146124C, was decreased in SLE (SLE: 83.1%, control: 87.9%, permutation P=0.0014).

To examine the functional significance of the risk haplotype, IRF2 region containing the promoter region, exon 1 and the 5’ part of intron 1 encompassing rs66801661 and rs62339994, which was in tight LD with rs13146124, were inserted upstream of the luciferase gene. Three constructs corresponding to the naturally-occurring haplotypes were transfected, and the luciferase activities were compared. The construct carrying both of the risk alleles, rs66801661A and rs62339994A (in LD with rs13146124T), was associated with the highest transcriptional activity in Jurkat cells under IFNγ stimulation (ANOVA, P=1.3X10-4).

Conclusion:

IRF2 polymorphisms are associated with susceptibility to SLE in a Japanese population. The SLE risk haplotype appeared to be associated with transcriptional activation of IRF2.


Disclosure:

A. Kawasaki,
None;

H. Furukawa,
None;

N. Nishida,
None;

E. Warabi,
None;

Y. Kondo,
None;

S. Ito,
None;

I. Matsumoto,
None;

M. Kusaoi,
None;

A. Suda,
None;

S. Nagaoka,
None;

K. Setoguchi,
None;

T. Nagai,
None;

S. Hirohata,
None;

K. Tokunaga,
None;

Y. Takasaki,
None;

H. Hashimoto,
None;

T. Sumida,
None;

S. Tohma,
None;

N. Tsuchiya,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-functional-polymorphisms-in-irf2-with-systemic-lupus-erythematosus-in-a-japanese-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology